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An important phenomenon in tumor immunoiogy 
that has come under recent attention is the impact of 
oncogene activation in tumor cells on the sensitivity to 
lysis by immune effector cells. Several studies sug­
gested that transfer of an activated 'IU oncogene into 
cultured rodent fibroblasts induces susceptibility to 
natural killer cell (NK) -mediated lysis. Experiments 
using human tumor cells, however, have produced 
conflicting data on the effect of 'IU activation in this 
respect. In studying the activation of the oncogene c­
mye, which is often overexpressed in human mela­
noma, we have found that in cell lines expressing high 
levels ofMyc protein, the sensitivity to lysis by NK cells 
was dramatically increased due to reduced expression 
of Human Leukocyte Antigen B locus products. Since 
the N-,as oncogene was found to be activated in 15% of 
T he acquisition of transforming properties is a dramatic event in the development of a tumor cell, reflected by a number of phenotypic changes. Such changes might elicit an immunologic response, resulting in genera­tion of either tumor antigen-specific cytotoxic T 
lymphocytes (CTL), or modulation of tumor cell sensitivity to nat­
ural killer (NK) cells. The basis for recognition of target cells by NK 
cells is still unknown [1,2], but several studies have indicated that 
reduced levels ofMHC class I may trigger lysis by NK cells [3-5]. 
NK cells may constitute a first line of defense against growing 
tumor cells [6], because there is no priming step required to activate 
their lytic activity. Furthermore, considering the effects of reduced 
MHC class I expression often found in tumor cells [7], NK cells may 
function as a defense system supplementary to CTL mediated lysis 
[8]. First identified as the transforming gene in the Harvey and 
Kirsten strains of murine sarcoma virus [9], the raJ gene encodes a 
protein (p21), that constitutes a major link in the signal transduction 
pathways starting with triggering of tyrosine kinase receptors at the 
cell surface [10-13]. Activation of raJ oncogenes is frequendy 
found in varying types of human tumors, including melanoma 
[14,15]. In many cases, it is unclear whether mutant raJ proteins are 
involved in the earlier stages of tumor initiation and growth or 
contribute to development of a fully malignant tumor phenotype. 
Several studies have addressed the question of whether raJ activation 
may influence the NK sensitivity of tumor cells, and may thereby 
enhance their sensitivity to the patients' immune system. Rodent 
Reprint requests to: PI Schrier, Department of Clinical Oncology, Uni­
versity Hospital, Building I, Kl-P, P.O. Box 9600,2300 RC Leiden, The 
Netherlands. 
human melanomas, we examined the possibility that 
in melanoma, in analogy to the murine systems, the 
mutated 'IU oncogene may influence NK susceptibility 
ofhaman melanoma cells. Two N-,IU genes harboring 
frequently found mutations were cloned into an ex­
pression vector. Transfection of the IGR39D mela­
noma cell line with wildtype and mutant N-,IU con­
structs yielded several ras-expressing clones that were 
tested for NK sensitivity. Neither high expression of 
the wildtype N-ras protein, nor expression of two mu­
tant proteins (N61-arg, N61-lys) was shown to result in 
enhanced NK-mediated lysis. We conclude that activa­
tion of rtI$ oncogenes does not lead to the induction of 
an NK-sensitive phenotype in human melanoma cells. 
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fibroblasts transformed by activated H- or K-raJ showed an NK 
sensitive phenotype [16-19], a finding that has been extended to a 
human breast cancer cell line, which upon transfection of activated 
H-raJ became highly susceptible to NK-mediated lysis (20). On the 
other hand, it has also been reported that this phenomenon may be 
cell type specific [21-23], and therefore an effect of raJ on NK 
sensitivity cannot always be anticipated. Previously, in a panel of 
human melanoma cell lines, we have found an association between 
mutation of endogenous ras and high NK sensitivity [24]. To estab­
lish if this relationship is causal, we set out to examine whether raJ 
oncogene transfection into a human melanoma cell line would in­
fluence the lysis by NK cells. Two commonly detected N-raJ muta­
tions were generated and transfected into the NK resistant mela­
noma cell line IGR39D, that earlier was shown to be induced to 
NK-sensitive phenotype by transfection of the c-myc oncogene [25). 
No enhanced lysis of N-ras transfected clones could be shown, 
indicating that in this human melanoma cell line N-ras mutation or 
overexpression does not induce elevated lytic susceptibility to NK 
cells. 
MATERIALS AND METHODS 
Cell Culture The human melanoma cell line IGR39D and its c-myc­
transfectant (referred to as IGR-myc, also clone 3) have been described 
elsewhere [26,27]. Cell lines and ras transfectants were cultured in DMEM 
supplemented with 8% fetal bovine serum (FBS). The NK-sensitive promy­
elocytic cell line K562 was grown in DMEM + 10% FBS. All cell lines were 
checked for mycoplasma infection and found to be negative. 
Plasmids and Mutagenesis The wildtype human genomic N-ras clone 
pBNras as well as the normal N-ras cDNA clone pcNt have been described 
before [28.29]. For mutagenesis the N-ras cDNA was subcloned from pcNl 
0022-202X/94/S07.00 Copyright © 1994 by The Society for Investigative Dermatology, Inc. 
1178 
118S van BLSAS ET AL 
by Ava II digestion and ligation into the Sma I site of pBSK + (Stratagene, La 
Jolla. CA). This vector was designated pBCR1 and used for in vitro muta­
genesis. For in vitro mutagenesis the following primers were used. The M13 
primer 5'-GT AAAACGACGGCCAGT -3' and reverse primer 5'­
CAGGAAACAGCTATGAC-3' hybridize to pBSK + vector sequences. For 
the generation of the 61-arg (61R) mutation the sense primer 5'-TA­
CAGCTGGACGAGAAGAGTACA-3' and anti-sense primer 5'­
TGTACTCTTCTCGTCCAGCTGTA-3' were utilized. Similarly. for 
the 61-lys (61K) mutation the sense 5'-TACAGCTGGAAAAGAAGAG­
TACA-3' and anti-sense 5'-TGTACTCTTCTTT CCAGCTGTA-3' 
primers were synthesized. Polymerase chain reaction (PCR) based mutagen­
esis was done according to the general method as described by Higuchi et al 
[30]. In a first round of amplification a 5' and a 3' fragment of the N-ras 
cDNA were generated in separate reactions. using a primer hybridizing to 
pBCR1 vector sequences in combination with a primer containing a point­
mutation as the indicated codon. Both 5' and 3' fragments were purified and 
mixed for a second round of amplification with the vector binding primers 
only, resulting in a full-length N-ras eDNA containing the indicated point­
mutation. After digestion with Sad and KpnI the cDNA was cloned into 
pBSK+. The integrity of the eDNA seCJuences was verified by PCR-SSCP 
analysis [31] and sequencing. The SacIjKpnI fragment was subcloned into 
the BamHI site of the expression vector pCMV neo [32] . Finally. the expres­
sion vectors were tested in a focus forming transformation assay using Rat-2 
fibroblast cells. 
Transfection and Selection Transfection of IGR39D was performed 
using the calcium-phosphate method [33]. with two 10 Jlg of the N-ras 
vector. mixed with 0.5 to 1 Jlg of pSV2neo. when appropriate. Transfected 
cells were selected in medium containing 600 Jlg/ml of G418 (Gibco BRL. 
Paisley. Scotland). Transfectants were screened for genomic integration of 
the N-ras eDNA by PCR. 
Western Analysis Whole cell extracts were prepared using 0.14 M 
NaCl, 0.2 M triethanolamine. 0.2% Na-deoxycholate. and 0.5% Nonidet 
P-40. supplemented with 1 mM phenylmethylsulphonyl fluoride and 
0.2 mg/ml aprotonin. Extracts were quick frozen twice and centrifuged to 
remove debris. Fifty micrograms of total protein was separated on sodium 
dodecylsulfate-polyacrylarnide gel electrophoresis (SDS-PAGE) and blot­
ted to PVDF membranes (Tropix, Bedford, MA). Immunodetection was 
performed using the rat monoclonal antibody Y13-259 [34] at 1 : 400 dilu­
tion. Second antibody incubations were carried out using goat-anti-rat con­
jugated to Alkaline Phosphatase (1 : 2500, Promega. Madison. WI) and the 
chemiluminescent substrate CPSD (Tropix) according to manufacturers' 
instructions. Membranes were exposed to Fungi RX X-Ray film for 30 
seconds. 
Cytotoxicity Assays Cytotoxicity assays were carried out as described 
before [25] in a standard 4-h chromium release assay. using as effectors 
peripheral blood mononuclear cells freshly isolated from a healthy donor. 
Serologic Reagents and FACS Analysis Cell surface expression of 
HLA class I and adhesion molecules was determined using the following 
antibodies: W6/32 (Sera Lab. Crawley Down. Sussex. UK). specific for a 
monomorphic epitope ofHLA-A.-B and -C; 4E [35]. recognizing all HLA­
Band -C alleles. in addition to those of the HLA-Aw19 crossreactive group; 
Fl0.2 (a generous gifr of A. Bloem. Dept. of Immunology. Utrecht, the 
Netherlands). specifically staining ICAM-l; TS2/9. recognizing LFA-3 
[36] . Cells were trypsinized. washed, and suspended in PBS. containing 
0.5% (w/v) BSA and 0.02% NaN] (PBA). After a 30-min incubation at 
4° C with first antibody. cells were washed three times with PBA and 
incubated for another 30 min with fluorescein-conjugated goat-anti-mouse 
antibody (Nordic Immunological Laboratories. Tilburg, the Netherlands). 
Finally cells were washed again and analyzed using a FACScan fluorocyto­
meter (Becton Dickinson. Mountainview. CA). 
RESULTS 
Generation ofN-ras Transfectants Using a panel of 14 human 
melanoma cell lines, we have previously found that the presence of 
mutated N-ras alleles correlated with high sensitivity to NK-me­
diated lysis [24]. To investigate whether this augmentation was 
actually caused by expression of mutant Ras proteins, a cell line with 
low sensitivity to NK lysis, IGR39D, was chosen for transfection 
experiments. 
The 61-arg {N61R} and 61-lys {N61K} mutations are frequently 
found in varying types of tumors [15], including melanoma {our 
unpublished observations}. These two mutations were introduced 
into the cDNA clone of human N-ras, using PCR mutagenesis. The 
mutant cDNA constructs were placed under the control of the 
THE JOURNAL OF INVESTIGATIVB DERMATOLOGY 
A. 
p21 ... 
B. 
p21 ... . 
_--- 20 kOa 
Figure 1. N-ra.s p21 expression in IGR39D and its derivatives. N-ras 
p21 protein expression levels of the IGR39D cell line and transfectants were 
assayed by Western blotting. A, lane 1 control Hras13 extract. lane 2, 
IGR39D, lane 3, IGR-neol.1ane 4, IGR-neo2, lanes 5 -7, IGR-Ql, -Q4, and 
-Q2 as indicated. B, lane 1, IGR39D, lanes 2-8, IGR-Ql . -Q2. -Q3. -R1, 
-R2. Kl. -K2 as indicated. 
CMV immediate early promoter/enhancer to induce high expres­
sion in melanoma cell lines {see below}. We also tested the trans­
forming ability of these CMV -driven ras plasmids in a Rat-2 fibrob­
last focus assay and found them to be at least as potent in 
transformation as the EJ H-ras {H-ras gene carrying a 12-val muta­
tion} oncogene {data not shown}. The pBNras plasmid, containing 
the wildtype genomic clone of human N -ras with its own promoter 
region, and the mutant N-ras constructs were transfected into 
IGR39D. The wildtype genomic N-ras gene was transfected to test 
whether a mere overexpression of p21 would already exert an effect 
on the NK phenotype of these melanoma cells. The resulting clones 
were tested for expression of the exogenous p21N., .. by Western 
blotting. A cell extract from the wildtype H-ras overexpressing cell 
line Hras13 [37] was included as a control (Fig tAl. The parental 
cells and control clones IGR-neol and -ne02 showed low basal 
levels of endogenous wildtype p21 (Table I. Fig tAl. Several 
clones expressing wildtype and mutant N -ras protein were obtained 
after transfection. Because the frequency of G418 resistant colonies 
expressing the mutant p21 was found to be very low, a prescreening 
procedure was divised, using PCR amplification of exons 1 and 2 to 
,check for integration of the transfected cDNA. In five out of eight 
wildtype clones we found raised p21 levels, whereas in a similar 
experiment only six out of 61 clones transfected with mutant ras 
yielded detectable p21 expression. All clones listed in Table I were 
found to have integrated exogenous ras {data not shown}. Clones 
IGR-Q1 , -Q2 and -Q4 express high levels of the exogenous wild­
type N-ras, whereas clone IGR-Q3 harbored integrated copies of a 
wildtype N-ras cDNA, but did not show evidence of protein ex­
pression (Fig tA,B). The mutant cDNA constructs resulted in a 
number of clones showing varying p21 levels, IGR-R1 and -R2 
having a fair expression of 61-arg N-ras, whereas IGR-K1 produced 
a very high amount of 61-lys p21. The IRG-K2 transfectant was 
positive for integration, but no detectable mutant p21 could be seen 
in these cells (Fig tB). 
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Table I. P21ras Expression Levels ofTransfectants' 
Clone 
IGR39D 
IGR-myc 
IGR-neol 
IGR-Ql 
IGR-Q2 
IGR-Q3 
IGR-Rl 
IGR-R2 
IGR-Kl 
IGR-K2 
Transfected with 
neo+c-myc 
neo 
neo + wt N-ras 
neo + wt N-ras 
ReO + wt N-ras 
neo + 61R N-ras 
neo + 61R N-ras 
neo + 61K N-ras 
neo + 61K N-ras 
N-ras Protein Expression! 
++ 
++ 
± 
+ 
+ 
++ 
'IGR39D clones carry wildtype (IGR-Q1. -Q2. -Q3) or mutant 61-arg (IGR-R1. 
-R2) or 61-lys (IGR-K1. -K2) N-rasconstructs. IGR-myc. ,-my, overexpressing clone; 
IGR-neol. a control neo transfectant. 
I p21 levels are indicated by - (no expression), + (moderate). or ++ (high). One 
clones showed either low or no expression (±) in different cell extracts. 
NK Sensitivity of Mutant ras Expressing Clones The influ­
ence of exogenous p21 expression in the IGR39D cell line on lysis 
by NK cells was evaluated, using freshly isolated peripheral blood 
mononuclear cells (PBMC) from a healthy donor as effector cells. 
The K562 promyelocytic cell line was used as a positive control for 
NK activity in the PBMC isolate. IGR-myc was taken as a positive 
control for the induction ofNK sensitivity in the IGR39D cell line. 
c-my' transfection of this line was r.reviously shown to induce 
strongly enhanced NK sensitivity [25 . In the present experiments, 
IGR-myc was two to four times more susceptible to NK cells as 
compared to the parental cell line (Figs 2,3). 
Two clones overexpressing wildtype N-Ras (IGR-Q1 and -Q2) 
showed little, if any, alteration of NK sensitivity (Fig 2B,C), also 
when compared to control neo transfectants, of which a representa­
tive clone is shown in Fig 2A (IGR-neo). Clone IGR-Q3, which 
had integrated ras DNA but did not produce p21, was equally well 
lysed by NK cells. These findings indicate that mere overexpression 
of (wildtype) p21 does not induce NK susceptibility. Two clones 
expressing comparable amounts of the 61-arg (R) N-Ras protein, 
were obtained from two independent transfection experiments 
(IGR-R1 and -R2). NK lysis of these transfectants was similar to 
that of the parental cell line and the IGR-neo control (Fig 3A,B). 
We observed the same effect when two 61-lys (K) mutants were 
tested. The IGR-K1 clone, expressing rather high levels of the 
activated protein even shows a slight decrease in NK lysis (Fig 3C). 
On the other hand, clone IGR-K2, in which the 61K protein is not 
detectable seems to be more sensitive than the parental IGR39D 
cells (Fig 3D). These fluctuations therefore seem to be a conse­
quence of clonal variation, rather than of direct effects of activated 
ras. A third 61K clone producing similar amounts of p21 as the 61R 
mutants, was equally sensitive to NK mediated lysis as the parental 
and the neo-transfected cells (data not shown). 
When LAK cells (lymphokine activated killer cells PBMC stim­
ulated for 5 - 7 d in vitro with interleukin-2) were used as effectors, a 
slightly decreased sensitivity was observed for clones IGR-Q1, -Q2, 
and -R1, but not for the other clones described here (results not 
shown). The NK and LAK data were similar with PBMC isolated 
from one other (healthy) individual. These experiments altogether 
$how that ras transfected melanoma cells are not more prone to 
NK-mediated cytolysis. 
Cen Surface Expression ofHLA Class I and Adhesion Mole­
cales To investigate whether possible effects of ras transfection 
on accessory molecules involved in determining NK susceptibility 
might have obscured or counteracted an effect of ras on NK sensi­
tivity, we analyzed HLA class I, ICAM-1 and LFA-3 expression of 
these transfectants. FACS analysis of HLA class I and HLA-B,-C 
locus products showed downregulated expression on the c-myc 
ttansfected, NK-sensitive clone IGR-myc, as compared to the pa­
rentallGR39D cells (Table n). To a lesser degree, the same obser­
vation was done for IGR-R2, but this was not accompanied by 
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Figure 2. NK susceptibility ofwlldtype N-ras traDSfectants. Periph­
eral blood mononuclear cells were freshly isolated from a healthy donor, and 
used as NK effector cells in a standard 4-h chromium release assay. The K562 
cell line was included as a control for the lytic activity of the effectors. A 
shows lysis of IGR-neo, in addition to the lysis of parental IGR39D, its 
c-myc transfectant IGR-myc, and the control cell line K562. InB, C andD, 
the NK sensitivity is indicated by three clones expressing elevated levels of 
wildtype N-ras, IGR-Ql,-Q2 and -Q3, respectively. Open squares represent 
the lysis ofK562; open circles, IGR39D; open triangles, IGR-myc; closed circles, 
the indicated transfected clone. 
enhanced NK sensitivity. Expression ofICAM-1 was found to be 
variable on several clones including the neo-transfectants, hinting to 
clonal polymorphism for this marker. No consistent differences, 
however, were found with the NK sensitivity data. Apparently, in 
the clones showing less ICAM-l expression, the down modulation 
was not strong enough to abolish NK resistance. LF A-3 expression 
was unchanged on all transfectants. 
DISCUSSION 
Immune Surveillance Against Induction and Growth of 
Tumor Cells The immune surveillance theory predicts that a 
major defense mechanism against tumor cells is constituted by the 
cellular immune system [8]. It has been established that CTL re­
sponses can occur in patients with various forms of human cancer 
including melanoma. For melanoma, tumor s�ecific peptides that 
elicit a CTL response have been characterized l38]. In mice, a CTL 
response against activated ras protein epitopes can be instigated 
[39,40]. Also, a specific reaction ofNK cells against tumor cells that 
express activated ras, has been observed for human tumors [20] . This 
last observation however, seems to be dependent on the cell type 
that is used [22]. We have previously found that transfection of 
c-myc into human melanoma cell lines resulted in a reduction of 
HLA expression, especially of B locus antigens [26], leading to 
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Figure 3. NK susceptibility of mutant N-ras transfectants. The 
IGR39D clones transfected with mutant N-ras as indicated in Table I, were 
tested for their sensitivity to NK mediated lysis. A shows the lysis of the 61R 
clone IGR-Rl, B, C, and D show results obtained with clones IGR-R2, -KI, 
and -K2 respectively. Open squares represent the lysis ofK562; open circles, 
IGR39D; open triangles, IGR-myc; marked by closed circles are rhe four mutant 
N-ras clones. 
elevated lytic susceptibility to NK cells [25]. This implies that on­
cogene activation, as in the case of c-myc, can be involved in the 
regulation of phenotypical aspects important for immune recogni­
tion [41]. In a number of human melanoma cell lines high NK 
sensitivity was found to be associated with the presence of a mutated 
N-ras allele [24]. Here, we explored the possibility that ras activa­
tion may, directly or through some other cell component, induce 
sensitivity to NK-mediated lysis in human melanoma cells , similar 
to what has been reported for murine cells. The well-described cell 
line IGR39D was transfected with several wildtype and mutant 
plasmid constructs. 
Generation ofMatant ras Expressing Melanoma Cells The 
isolation of four clones overexpressing wildtype N-Ras and four 
transfectants with varying expression of mutant p21 is described in 
this paper. In our experience, obtaining cells with the correct inte­
gration and expression of mutated N-ras gene constructs after trans­
fection is a rather infrequently occurring event, especially when 
compared to transfections using the wildtype genomic fragments. 
We do not have an explanation for this phenomenon, but a sugges­
tion may be that expression of activated p21 has a profound effect on 
the survival of recipient cells. It is well known, that activating point 
mutations in the Ras protein enhance the proliferative capacity of a 
tumor cell in early development. This may not, however, be the case 
in already malignant tumor cells, or cells adapted to culture condi­
tions. Aberrant expression of the Ras protein in these cells may lead 
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to cell death, because it is known that unscheduled entry into mito­
sis, as for instance induced by expression of a mutant Ras, may 
trigger the process of apoptosis. The clones with mutated ras that 
were isolated and studied here, are apparently resistant to ras-in­
duced apoptosis. In these clones the expression of several molecules 
involved in recognition and lysis by NK cells and CTL such as HLA 
class I and adhesion molecules was found not to be changed grossly, 
as compared to the parental cell line. Analogous to the NK sensitive 
clone , IGR-myc, but not to the same extent, the ras tranfectant 
IGR-R2 showed decreased HLA-B,-C expression, in this case not 
followed by NK susceptibility. This may suggest a threshold level 
of HLA class I is necessary to protect against lysis by NK cells. 
IGR-R2 may then still express enough HLA-B and -C locus prod­
ucts for protection to NK mediated lysis, as opposed to IGR-myc. 
Activation of ras Does Not Determine NK Sensitivity The 
IGR39D clones transfected with mutant and wildtype N-ras, were 
found to possess an unaltered susceptibility to NK-mediated lysis. If 
ras activation is lethal for these melanoma cells (see above), then 
surviving colonies as used here for determining NK sensitivity must 
have undergone additional changes to survive. These changes po­
tentially could mask a regular effect of mutated ras on NK suscepti­
bility, which would weaken our conclusion that ras activation by 
mutation is not linked to determining the NK phenotype. On the 
other hand, excessive production of wildtype p21 in some experi­
mental systems induces identical effects as compared to the mutant 
analogue [42], and in a number of human tumors it has been shown 
that overexpression of wildtype ras is associated with poor prognosis 
[43-46]. Therefore , our clones with overexpressed wildtype p21 
may be considered as representative for ras-activated cells. These 
clones could be easily obtained, and possessed unaltered NK suscep­
tibility. This corroborated our conclusion that ras activation is not 
involved in modulation of NK sensitivity in melanoma. 
Activated ras Involved In Early Steps of Metastasis? In a 
recent study using a colon carcinoma cell line, it was shown that 
activated ras induces NK resistance, concomitant with the induction 
of a more differentiated phenotype of the tumor cells [22]. It has 
been speculated that ras activation or amplification might be an 
important step preceding the acquisition of metastasizing capacity 
[44,47]. In view of this, it is understandable that activation of the 
p21 protein induces resistance to NK cells , because it facilitates the 
successful entry into the circulation and colony-formation at distant 
sites in the body. We could not demonstrate prominant NK resist­
ance following N-ras transfer, but several of the tested clones were 
slightly less susceptible to NK or LAK lysis. It will be interesting to 
see whether metastasizing capacity in immunocompetent mice is 
enhanced in these particular ras transfectants. 
TableD. Cell Surface Expression of HLA Class I and 
Adhesion Molecules on IGR39D and Its Transfectants· 
Clone HLA class I HLA-B,-C IC�-l LFA-3 
f 
IGR39D +++ +++ ++/+ ++ 
IGR-myc ++ + + ++ 
IGR-neo1 +++ +++ + ++ 
IGR-Ql +++ +++ + ++ 
IGR-Q2 +++ +++ ++ ++ 
IGR-Q3 +++ +++ ++ ++ 
IGR-R1 +++ +++ + ++ 
IGR-R2 +++ ++ ++ + 
IGR-Kl +++ +++ ++ ++ 
IGR-K2 +++ +++ ++ ++ 
• Parental, control, and ras transfected cells were tested for expression ofHLA class I 
(W6/32 antibody), HLA-B,-C (4E), ICAM-l (F10.2). and LFA-3 (TS2/9) by FACS 
analysis. Expression levels are denoted as strongly positive (+++). positive (++). or 
weakly positive (+). 
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